Clinical Trials
Zeno (zenocutuzumab, or MCLA-128) is being developed for the potential treatment of NRG1 fusion (NRG1+) lung, pancreas and other cancers. Our eNRGy trial, a phase 1/2 clinical trial is an ongoing open-label, multicenter trial enrolling patients with NRG1+ solid tumors. Encouraging clinical activity has been reported at the 2022 ASCO Annual Meeting.
Further details about the eNRGy clinical trial for Zeno, including current trial sites, can be found at Merus’ trial website at http://www.nrg1.com or by calling 1-833-NRG-1234.
More information is available at the clinicaltrials.gov website.
Patients with NRG1+ cancer that are otherwise unable to participate in an applicable clinical trial may be eligible to participate in the Early Access Program for Zeno (MCLA-128). Further details about the Zeno Early Access Program can be found at Merus’ trial website www.nrg1.com or by calling 1-833-NRG-1234. Details on Merus’ Early Access Policy are available here. Information is also available at the clinicaltrials.gov website: Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor
Zeno (zenocutuzumab, or MCLA-128) is being developed in combination with afatinib for the potential treatment of NRG1+ non-small cell lung cancer, and in combination with androgen deprivation therapy in castration-resistant prostate cancer. Our phase 2 clinical trial is ongoing.
More information is available at the clinicaltrials.gov website.
(Petosemtamab)
Petosemtamab (MCLA-158) is being developed for the potential treatment of solid tumors. Our phase 1/2 clinical trial of petosemtamab is ongoing in the dose expansion phase of the open-label, multicenter trial. Enrollment of patients in dose expansion cohorts continues and early evidence of clinical activity in advanced Head & Neck Squamous Cell Carcinoma has been observed.
More information is available at the clinicaltrials.gov website.
MCLA-129 is currently being developed for the potential treatment of advanced non-small cell lung cancer (NSCLC) and other solid tumors. Our phase 1/2 trial is ongoing in the dose expansion phase of the open-label, multicenter trial. Enrollment of patients in dose expansion cohorts continues, evaluating MCLA-129 monotherapy in EGFR ex20 NSCLC, MET ex14 NSCLC, and in head and neck squamous cell carcinoma, as well as MCLA-129 in combination with Tagrisso (osimertinib), a third generation EGFR TKI, in treatment-naïve EGFR mutant (m) NSCLC and in EGFRm NSCLC that has progressed on Tagrisso.
More information is available at the clinicaltrials.gov website.
MCLA-145 is currently being developed for the potential treatment of solid tumors. Our phase 1 open-label, multicenter, dose escalation trial is ongoing, including a safety dose expansion phase and in combination with Keytruda (pembrolizumab) a PD1 inhibitor, to be followed by a planned dose expansion phase in patients with solid tumors.
More information is available at the clinicaltrials.gov website.
Unless otherwise noted, we are providing this information as of February 28, 2023, This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Merus’ most recent Annual Report on Form 10K and in Merus’ other periodic reports on Form 10-Q and Form 8-k filed with the SEC, and actual results may vary materially. Merus provides this information as of the date above and does not undertake any obligation to update any forward-looking statements contained on these tables as a result of new information, future events or otherwise.
All Company therapeutic candidates described or mentioned herein are investigational and have not yet been approved for marketing by any regulatory authority.